{"id":71436,"date":"2026-05-20T11:25:00","date_gmt":"2026-05-20T11:25:00","guid":{"rendered":"https:\/\/medsbase.com\/hcg-peptide\/"},"modified":"2026-05-21T07:14:08","modified_gmt":"2026-05-21T07:14:08","slug":"hcg-peptide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/hcg-peptide\/","title":{"rendered":"HCG (Humaan Choriongonadotrofine) \u2014 Onderzoekskwaliteit"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is HCG (research-grade)?<\/h3>\n

HCG<\/strong> (Human Chorionic Gonadotropin) is a glycoprotein hormone composed of two non-covalently associated subunits (\u03b1, 92 amino acids \u2014 shared with LH\/FSH\/TSH; \u03b2, 145 amino acids \u2014 unique to HCG), with an approximate combined molecular weight of ~36.7\u00a0kDa. It is the canonical pharmacological tool for activating the LH\/CG receptor (LHCGR)<\/strong> on Leydig cells (driving testosterone production in male research models) and ovarian theca \/ granulosa cells (driving follicular maturation and ovulation in female reproductive research). The research-grade material supplied here is the urinary-extracted glycoform (CAS 9002-61-3) at \u226599% HPLC purity, lyophilized in 5,000 IU or 10,000 IU vials. It is functionally distinct<\/em> from the recombinant rHCG (choriogonadotropin alfa, CAS 56832-30-5) used in some clinical preparations. Supplied for laboratory research use only.<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Lyophilized \u226599% HPLC-verified urinary-extracted HCG \u00b7 COA available on request \u00b7 Discreet temperature-stable packaging \u00b7 Worldwide research-supply courier \u00b7 1,400+ verified klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
Compound Class<\/strong><\/td>\nHeterodimeric glycoprotein hormone (\u03b1 + \u03b2 subunits); LH\/CG receptor (LHCGR) agonist; peptide hormone<\/td>\n<\/tr>\n
Chemical Name<\/strong><\/td>\nHuman Chorionic Gonadotropin (urinary-extracted glycoform; uHCG)<\/td>\n<\/tr>\n
CAS-nummer<\/strong><\/td>\n9002-61-3 (urinary HCG); 56832-30-5 (recombinant choriogonadotropin alfa \u2014 not the form supplied here)<\/td>\n<\/tr>\n
Subunit Structure<\/strong><\/td>\nHeterodimer of two non-covalently associated subunits: \u03b1-subunit (92 amino acids, shared with LH \/ FSH \/ TSH) and \u03b2-subunit (145 amino acids, unique to HCG). Both subunits are extensively N- and O-glycosylated \u2014 the high sialic-acid content of \u03b2-subunit is responsible for HCG’s exceptionally long plasma half-life relative to LH.<\/td>\n<\/tr>\n
Moleculair gewicht<\/strong><\/td>\n~36,700 Da (~36.7\u00a0kDa) combined heterodimer; \u03b1-subunit ~14\u00a0kDa, \u03b2-subunit ~22\u00a0kDa (heavily glycosylated)<\/td>\n<\/tr>\n
Molecuulformule<\/strong><\/td>\nHeterodimeric glycoprotein \u2014 \u03b1-subunit (92 aa, shared with LH\/FSH\/TSH) + \u03b2-subunit (145 aa, hCG-specific). Heavy sialylation (~30% w\/w carbohydrate) gives 33\u201337 h plasma half-life. No single molecular formula because of variable glycoform composition; protein-only MW ~25 kDa, fully glycosylated MW ~36.7 kDa.<\/td>\n<\/tr>\n
Werkingsmechanisme<\/strong><\/td>\nBinds and activates the LH\/CG receptor (LHCGR<\/strong>) \u2014 a Gs-coupled GPCR expressed on Leydig cells (testis) and ovarian theca \/ granulosa cells. Receptor activation drives adenylate cyclase, raises intracellular cAMP, activates PKA, and induces the steroidogenic enzymes (StAR, CYP17A1, CYP11A1) that drive de-novo testosterone biosynthesis (male) or oestrogen\/progesterone biosynthesis (female). HCG and LH share the same receptor and the same downstream cascade.<\/td>\n<\/tr>\n
IU-to-mg conversion<\/strong><\/td>\n~9,300 IU per mg highly purified material (WHO 5th International Standard reference). 1 IU is therefore approximately 108 ng of pure peptide. A 5,000 IU vial contains ~0.54 mg of peptide; a 10,000 IU vial contains ~1.08 mg.<\/td>\n<\/tr>\n
Plasma Half-Life<\/strong><\/td>\nBiphasic elimination \u2014 initial phase ~6 h, terminal phase 33\u201337 h. Substantially longer than LH (~20 min) \u2014 driven by the high sialic-acid content of the \u03b2-subunit glycans, which reduces hepatic clearance.<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyophilized white-to-off-white amorphous powder; single-use research vials. Supplied with a separate stopper-sealed lyophilized cake (no in-vial diluent).<\/td>\n<\/tr>\n
Zuiverheid<\/strong><\/td>\n\u226599% (HPLC verified); WHO bioassay confirms LHCGR-binding potency consistent with the 5th International Standard. COA available on request.<\/td>\n<\/tr>\n
Oplosbaarheid<\/strong><\/td>\nReconstitute in bacteriostatic water (the standard research-supply diluent) at 1.0 mL per 5,000 IU (\u2192 5,000 IU\/mL working stock) or 2.0 mL per 10,000 IU (\u2192 5,000 IU\/mL); other dilutions per protocol. Mannitol-based lyophilization cake dissolves rapidly with gentle swirling \u2014 do not shake. Avoid vortexing (high-shear can dissociate the \u03b1\/\u03b2 heterodimer).<\/td>\n<\/tr>\n
Opslag<\/strong><\/td>\nLyophilized: 2\u20138 \u00b0C unopened for short-term working stock; \u221220 \u00b0C for long-term storage (stable \u226536 months at \u221220 \u00b0C; \u226518 months at 2\u20138 \u00b0C). Reconstituted: 2\u20138 \u00b0C, use within ~30 days. Protect from light. Do not freeze reconstituted material<\/strong> \u2014 freeze-thaw cycles dissociate the \u03b1\/\u03b2 heterodimer and destroy bioactivity.<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nFor laboratory research use only. Not for human or veterinary diagnostic or therapeutic use. HCG is on the World Anti-Doping Agency (WADA) Prohibited List (class S2, Peptide Hormones, Growth Factors and Related Substances) and is prohibited at all times in male athletes (the female-athlete exemption reflects HCG’s role as a natural pregnancy hormone). Researchers in human-subject contexts should be aware of this regulatory status.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is HCG?<\/h2>\n

HCG<\/strong> (Human Chorionic Gonadotropin, CAS 9002-61-3) is a glycoprotein peptide hormone in the same gonadotropin family as luteinising hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). Like the other three, it is a heterodimer of an \u03b1-subunit (92 amino acids, identical across all four hormones) and a \u03b2-subunit (145 amino acids, unique to HCG). The \u03b1 and \u03b2 subunits are non-covalently associated and both are extensively glycosylated \u2014 the \u03b2-subunit alone carries four N-linked and four O-linked glycans, and the high sialic-acid content of these glycans is responsible for HCG’s exceptionally long plasma half-life relative to LH (33\u201337 h terminal, versus ~20 min for LH).<\/p>\n

Endogenous HCG is produced by the syncytiotrophoblast of the developing placenta during pregnancy, where it maintains the corpus luteum and progesterone production for the first ~10 weeks of gestation. Outside pregnancy it is not normally present at detectable levels; its appearance in serum or urine is therefore the basis of pregnancy testing. The pharmacological utility of HCG in research, however, has nothing to do with this physiological role and everything to do with the fact that HCG binds and activates the same LH\/CG receptor (LHCGR) as endogenous LH \u2014 but with far longer duration of action. HCG is therefore the standard pharmacological tool for sustained LHCGR activation in research that probes Leydig-cell function, gonadal steroidogenesis, spermatogenesis, follicular development, ovulation, and the HPG axis broadly.<\/p>\n

Two molecular forms of HCG exist in commerce: the urinary-extracted form (uHCG<\/strong>, CAS 9002-61-3), purified from the urine of pregnant women, which is what we supply; and the recombinant form (rHCG<\/strong> or choriogonadotropin alfa, CAS 56832-30-5), produced in CHO cells and used in some clinical preparations (Ovidrel \/ Ovitrelle). The two forms have the same amino-acid sequence and the same LHCGR binding profile, but the glycosylation patterns differ slightly between urinary-extracted and CHO-cell expression \u2014 published bioassay comparisons report broadly equivalent in-vivo potency.<\/p>\n

Mechanism of Action \u2014 LH\/CG Receptor Activation and Steroidogenesis<\/h2>\n

HCG’s mechanism is among the most-characterised in endocrine pharmacology:<\/p>\n